Key Points Moderna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough. This product could rival the lifetime sales of Moderna's coronavirus vaccine. Moderna's deep pipeline makes the stock even more attractive. 10 stocks we like better than Moderna › Moderna (NASDAQ: MRNA) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies. This new product should meaningfully contribute to the biotech's financial results over the medium term.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.